Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension

Condition(s) targeted: Hypertension

Intervention: Micardis® plus (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Study to evaluate efficacy and tolerability of Micardis® plus under usual daily-practice prescribing-conditions

Official title: Post-Marketing Surveillance Study Micardis® Plus

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Change from baseline in morning blood pressure

Change from baseline in classification of blood pressure

Secondary outcome:

Number of patients with adverse drug reactions

Assessment of efficacy by investigator on 5-point scale

Assessment of tolerability by investigator on a 5-point scale

Change from baseline in heart rate

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult (Age >= 18 years) males and females for whom a medical antihypertensive therapy

is indicated Exclusion Criteria:

- Age < 18 years

Starting date: June 2002
Last updated: September 11, 2014